General MedicationsORALGeneric

ALOGLIPTIN; METFORMIN HYDROCHLORIDE

Standard Dose

EQ 12.5MG BASE;1GM

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: None (Tentative Approval)

Summary

Approval overview ALOGLIPTIN; METFORMIN HYDROCHLORIDE is listed in Drugs@FDA under application 210160 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ALOGLIPTIN; METFORMIN HYDROCHLORIDE Form and strength TABLET;ORAL - EQ 12.5MG BASE;1GM Sponsor TORRENT PHARMS LTD Submission history Latest submission status date: 2018-12-19 00:00:00.

Structured Monograph

Clinical summary

Approval overview ALOGLIPTIN; METFORMIN HYDROCHLORIDE is listed in Drugs@FDA under application 210160 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ALOGLIPTIN; METFORMIN HYDROCHLORIDE Form and strength TABLET;ORAL - EQ 12.5MG BASE;1GM Sponsor TORRENT PHARMS LTD Submission history Latest submission status date: 2018-12-19 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: None (Tentative Approval)
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.